ストックスクリーナーアプリを入手
1.81
2.84%
0.05
Fibrobiologics Inc (FBLG) 最新ニュース
FibroBiologics receives Australian patent for disc disease therapy - Investing.com
FibroBiologics receives Australian patent for disc disease therapy By Investing.com - Investing.com Canada
FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease - Morningstar
Hundreds of millions face disc disease; FibroBiologics' patent pairs cannabidiol and cell therapy - Stock Titan
FibroBiologics Says Preclinical Data Shapes Design of Further Studies for Degenerative Joint Treatment - Sahm
FibroBiologics reports cartilage repair in animal study By Investing.com - Investing.com South Africa
FibroBiologics reports cartilage repair in animal study - Investing.com
Animal joints showed cartilage repair within four weeks of one injection - Stock Titan
BRIEF-Fibrobiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair In Preclinical Study Of Degenerative Joints - Bitget
Armistice Capital discloses 9.99% FibroBiologics (FBLG) stake via Master Fund - Stock Titan
FibroBiologics Inc - Smartkarma
FBLG Q2 2026 Earnings: Narrower Loss Beats Estimates as Pre-Revenue Biotech Advances Fibroblast Pipeline - vinanet.vn
FBLG Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 7.77% Share GainEarnings Surprise Stocks - vinanet.vn
FibroBiologics receives patent for islet transplant method By Investing.com - Investing.com UK
FibroBiologics receives patent for islet transplant method - Investing.com
Fibrobiologics Granted US Patent Covering The Use Of Fibroblasts - TradingView
FibroBiologics Patent Could Help Stretch Scarce Donor Pancreases - Stock Titan
FibroBiologics (FBLG) Holds at $0.98 as Biotech Stock Tests Key Trading RangeFibonacci Extension - vinanet.vn
Fibrobiologics Inc (FBLG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
FBLG Q2 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesRevenue Report - vinanet.vn
Fibrobiologics Inc (FBLG) Stock News Today - TradingKey
FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage - marketscreener.com
FibroBiologics patent covers Sox9 turning fibroblasts into cartilage cells - Stock Titan
H.C. Wainwright cuts FibroBiologics price target to $6 on model adjustments - Investing.com
FibroBiologics Faces Material Clinical Trial and Regulatory Risks That Threaten Commercialization Timeline and Long-Term Outlook - TipRanks
FibroBiologics, Inc. Revenue Breakdown – NASDAQ:FBLG - TradingView
FBLG: Advanced clinical pipeline, reduced R&D costs, raised $12M, and expanded patent assets - tradingview.com
FibroBiologics Q2 EPS beats estimates as losses narrow 72.5% - scanx.trade
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate - PR Newswire
FIBROBIOLOGICS ($FBLG) Releases Q2 2026 Earnings - Quiver Quantitative
FibroBiologics, Inc. 2Q 2026: Net loss $(4.12M), EPS $(0.66) — 10-Q Summary - TradingView
FibroBiologics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Form DEF 14A FIBROBIOLOGICS For: 31 July By Investing.com - Investing.com Nigeria
FBLG Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Stage ContinuesEarnings Decline Risk - Vinanet
FBLG Q1 2026 Earnings: EPS Misses Slightly as Pre‑Revenue Biotech Continues R&D FocusForward EPS Estimate - vinanet.vn
Fibrobiologics Inc (FBLG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Fibrobiologics Inc (FBLG) Earnings Date & Reports & Earnings News - TradingKey
Fibrobiologics Inc (FBLG) Valuation: PE, PB & Fair Value Analysis - TradingKey
FBLG|Fibrobiologics Inc|Price:0.681|Chg%:-0.031 - TradingKey
Fibrobiologics Inc (FBLG) Institutional Confidence - TradingKey
Fibrobiologics Inc (FBLG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Fibrobiologics Inc expected to post a loss of 72 cents a shareEarnings Preview - TradingView
Fibrobiologics Inc (FBLG) Balance Sheet - TradingKey
FBLG|Fibrobiologics Inc|Price:0.712|Chg%:-0.024 - TradingKey
FibroBiologics Market Sentiment - Benzinga España
Fibrobiologics Inc (FBLG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fibrobiologics Inc (FBLG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
FBLG Q1 2026 Earnings: Narrow EPS Miss Against Estimates Amid Pre-Revenue Development Stage - vinanet.vn
FBLG|Fibrobiologics Inc|Price:1.020|Chg%:+0.152 - TradingKey
TradingKey - TradingKey
FibroBiologics Faces Nasdaq Delisting, Appeals Planned - TipRanks
FibroBiologics Received Notice of Delisting - TradingView
FibroBiologics (NASDAQ: FBLG) appeals Nasdaq move to delist its shares - Stock Titan
FBLG Q1 2026 Earnings: Pre-Revenue Biotech Reports In-Line Loss, Stock DeclinesPretax Income Report - vinanet.vn
FibroBiologics (FBLG) Q4 2025 earnings summary - Quartr
FibroBiologics (FBLG) Registration filing Summary - Quartr
FibroBiologics (FBLG) Proxy filing Summary - Quartr
FibroBiologics (FBLG) AGM 2026 Summary - Quartr
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):